Investment Thesis
Viatris exhibits severe operational deterioration with negative operating income, inability to cover interest expenses from operations (interest coverage: -0.7x), and nearly flat revenue growth (0.3% YoY). The 454% collapse in net income year-over-year combined with negative operating margins indicates fundamental profitability issues in the pharmaceutical business that threaten long-term debt serviceability despite positive free cash flow.
Strengths
- Positive free cash flow of $348.4M provides operational liquidity buffer
- Current ratio of 1.60x indicates adequate short-term liquidity position
- Gross margin of 32.9% demonstrates remaining product pricing power
Risks
- Negative operating income (-$79.7M) and negative interest coverage (-0.7x) indicates inability to service $12.4B debt from operations
- Net income collapsed 454% YoY with EPS down 466%, signaling severe operational deterioration and potential structural decline
- Revenue growth of only 0.3% YoY with ROE of 1.2% and ROA of 0.5% reflects weak competitive position and deteriorating asset utilization
- High debt leverage ($12.4B long-term debt) combined with negative operating performance creates solvency stress
Key Metrics to Watch
- Operating income return to positive territory and operating margin expansion
- Interest coverage ratio recovery above 2.0x to ensure debt serviceability
- Revenue growth acceleration above low single digits
- Free cash flow sustainability and operating cash flow trends
Financial Metrics
Revenue
3.5B
Net Income
176.4M
EPS (Diluted)
$0.15
Free Cash Flow
348.4M
Total Assets
36.8B
Cash
1.8B
Profitability Ratios
Gross Margin
32.9%
Operating Margin
-2.3%
Net Margin
5.0%
ROE
1.2%
ROA
0.5%
FCF Margin
9.9%
Balance Sheet & Liquidity
Current Ratio
1.60x
Quick Ratio
1.03x
Debt/Equity
0.85x
Debt/Assets
60.2%
Interest Coverage
-0.66x
Long-term Debt
12.4B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:47:13.215138 |
Data as of: 2026-03-31 |
Powered by Claude AI